Cited by 2,472Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and ApplicationsStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Open access

Seymour, Lesley, Bogaerts, Jan, Perrone, Andrea, Ford, Robert, Schwartz, Lawrence H, Mandrekar, Sumithra, Lin, Nancy U, Litière, Saskia, Dancey, Janet, Chen, Alice, Hodi, F Stephen, Therasse, Patrick, Hoekstra, Otto S, Shankar, Lalitha K, Wolchok, Jedd D, Ballinger, Marcus, Caramella, Caroline, de Vries, Elisabeth G E·2017·The Lancet Oncology

DOI 10.1016/s1470-2045(17)30074-8PMC PMC5648544

Open this paper in CoChat — free account

Abstract

Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour burden-a mainstay of evaluation of cancer therapeutics that provides key information about objective response and disease progression. A consensus guideline-iRECIST-was developed by the RECIST working group for the use of modified Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) in cancer immunotherapy trials, to ensure consistent design and data collection, facilitate the ongoing collection of trial data, and ultimate validation of the guideline. This guideline describes a standard approach to solid tumour measurements and definitions for objective change in tumour size for use in trials in which an immunotherapy is used. Additionally, it defines the minimum datapoints required from future trials and those currently in development to facilitate the compilation of a data warehouse to use to later validate iRECIST. An unprecedented number of trials have been done, initiated, or are planned to test new immune modulators for cancer therapy using a variety of modified response criteria. This guideline will allow consistent conduct, interpretation, and analysis of trials of immunotherapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(17)30074-8

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Self-citation
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Self-citation
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Show all 37 references

Sorted by citations

Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
A decade of immune-checkpoint inhibitors in cancer therapy
Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong, J., Chehrazi‐Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,307
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vogel, A., Cervantes, A. M. R., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J., Neumann, U. P., Ricke, J., Sangro, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy308 · Cited by 1,067
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
Self-citation
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., de Vijver, K. K. V., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 932
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer
Wang, F., Shen, L., Li, J., Zhou, Z., Liang, H., Zhang, X., Tang, L., Xin, Y., Jin, J., Zhang, Y., et al. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0349-9 · Cited by 811
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 810
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720
Self-citation
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Cohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B. A., Gillison, M. L., Harrington, K. J., Le, Q., Lee, N. Y., Leidner, R. S., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 733
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Janjigian, Y. Y., Kawazoe, A., Yanez, P. E., Li, N., Lonardi, S., Kolesnik, O., Barajas, O., Bai, Y., Shen, L., Tang, Y., et al. (2021) · Nature · doi:10.1038/s41586-021-04161-3 · Cited by 730
mRECIST for HCC: Performance and novel refinements
Llovet, J. M., & Lencioni, R. A. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.026 · Cited by 689
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Hendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 685
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
Wang, F., Zhang, X., Li, Y., Tang, L., Qu, X., Ying, J., Zhang, J., Sun, L., Lin, R., Qiu, H., et al. (2021) · 癌症：英文版 · doi:10.1002/cac2.12193 · Cited by 619
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
“Clearly defining the unconfirmed progressive disease (iUPD) is an important objective of this guideline.(218) Pseudoprogression (PP) and hyperprogression (HP) diseases are two states of iUPD that are difficult to distinguish in a short-term clinical observation.”
Background
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Janjigian, Y. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J. P., Yanez, P. E., Wyrwicz, L. S., Shen, L., Ostapenko, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02033-0 · Cited by 544
Clinical Challenges of Immune Checkpoint Inhibitors
Miguel, M. J. D., & Calvo, E. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.004 · Cited by 549
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 564
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522
Novel patterns of response under immunotherapy
Borcoman, É., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., Goel, S., Bedard, P. L., & Tourneau, C. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz003 · Cited by 529
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 505
“Immune RECIST (iRECIST) may be used to evaluate response in patients receiving treatment with immune-checkpoint inhibitors [280 4.”
Method
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
Herrera, F. G., Ronet, C., Ochoa-de-Olza, M., Barras, D., Crespo, I., Andreatta, M., Corria-Osorio, J., Spill, A., Benedetti, F., Genolet, R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0003 · Cited by 472
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Kim, R. D., Chung, V. M., Alese, O. B., El‐Rayes, B. F., Li, D., Al‐Toubah, T., Schell, M. J., Zhou, J.-M., Mahipal, A., Kim, B., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0930 · Cited by 455
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
Wang, F., Zhang, X., Tang, L., Wu, Q., Cai, M., Li, Y., Qu, X., Qiu, H., Zhang, Y., Ying, J., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12516 · Cited by 470
“In regard to immunotherapy, treatment efficacy can be evaluated by referring to the immune RECIST (iRECIST) criteria [9]. h Small sample-sized studies have shown that volume measurement [10] and functional imaging parameters such as the apparent diffusion coefficient value of diffusion-weighted MRI…”
Background
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
Self-citation
Current Landscape of Immunotherapy in Breast Cancer: A Review
Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7147 · Cited by 384
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
(2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 390
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 386
Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases
Ianiro, G., Punčochář, M., Karcher, N., Porcari, S., Armanini, F., Asnicar, F., Beghini, F., Blanco-Míguez, A., Cumbo, F., Manghi, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01964-3 · Cited by 366
Immunotherapy in breast cancer: an overview of current strategies and perspectives
Debien, V., Caluwé, A. D., Wang, X., Piccart, M. J., Tuohy, V. K., Romano, E., & Buisseret, L. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00508-3 · Cited by 397
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
Hodi, F. S., Ballinger, M., Lyons, B., Soria, J.-C., Nishino, M., Tabernero, J., Powles, T., Smith, D., Hoos, A., McKenna, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1644 · Cited by 366
Self-citation
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 366
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30671-0 · Cited by 357
Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges
Gandalovičová, A., Rösel, D., Fernandes, M., Veselý, P., Heneberg, P., Čermák, V., Petruzelka, L. B., Kumar, S., Sanz‐Moreno, V., & Brábek, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.008 · Cited by 350
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
Tazdait, M., Mezquita, L., Lahmar, J., Ferrara, R., Bidault, F., Ammari, S., Balleyguier, C., Planchard, D., Gazzah, A., Soria, J., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.017 · Cited by 354
Self-citation
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA), & National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 364
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
Taı̈eb, J., Svrcek, M., Cohen, R., Basile, D., Tougeron, D., & Phelip, J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.020 · Cited by 353
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
Necchi, A., Joseph, R. W., Loriot, Y., Hoffman-Censits, J. H., Perez‐Gracia, J. L., Petrylak, D. P., Derleth, C. L., Tayama, D., Zhu, Q., Ding, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx518 · Cited by 302
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
Delanoy, N., Michot, J., Comont, T., Kramkimel, N., Lazarovici, J., Dupont, R., Champiat, S., Chahine, C., Robert, C., Herbaux, C., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30175-3 · Cited by 302
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Kluger, H. M., Tawbi, H. A., Ascierto, M. L., Bowden, M., Callahan, M. K., Cha, E., Chen, H. X., Drake, C. G., Feltquate, D., Ferris, R. L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000398 · Cited by 309
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Zerdes, I., Matikas, A., Bergh, J. C. S., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 305
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 296
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
Kemp, R., & Prasad, V. K. (2017) · BMC Medicine · doi:10.1186/s12916-017-0902-9 · Cited by 296
Immunotherapy of Melanoma: Facts and Hopes
Weiss, S. A., Wolchok, J. D., & Sznol, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1550 · Cited by 284
Self-citation
Upfront FOLFOXIRI plus Bevacizumab with or without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (AtezoTRIBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial
Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00274-1 · Cited by 280
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
(2018) · New England Journal of Medicine · doi:10.1056/nejmc1808251 · Cited by 277
TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Han, J., Duan, J., Bai, H., Wang, Y., Wan, R., Wang, X., Chen, S., Tian, Y., Wang, D., Fei, K., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0398 · Cited by 266
Patterns of Response and Progression to Immunotherapy
Borcoman, É., Nandikolla, A. G., Long, G. V., Goel, S., & Tourneau, C. L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200643 · Cited by 267
FDG PET/CT for assessing tumour response to immunotherapy
Aide, N., Hicks, R. J., Tourneau, C. L., Lheureux, S., Fanti, S., & Lopci, E. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4171-4 · Cited by 266
Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
Hammerl, D., Martens, J. W. M., Timmermans, M., Smid, M., Trapman-Jansen, A. M., Foekens, R., Isaeva, O. I., Voorwerk, L., Balcioglu, H. E., Wijers, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25962-0 · Cited by 262
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
Bartolomucci, A., de Nóbrega, M., Ferrier, S. T., Dickinson, K., Kaorey, N., Nadeau, A., Castillo, A., & Burnier, J. V. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00876-y · Cited by 301
“An updated version was recently introduced for evaluating responses in patients treated withimmunotherapy,callediRECIST 3 .”
Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients
Rogado, J., Sánchez-Torres, J. M., Romero-Laorden, N., Ballesteros, A. I., Pacheco-Barcia, V., Ramos-Leví, A., Arranz, R., Lorenzo, A., Gullón, P., Donnay, O., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.014 · Cited by 255
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Rini, B. I., Battle, D. J., Figlin, R. A., George, D. J., Hammers, H. J., Hutson, T., Jonasch, E. W., Joseph, R. W., McDermott, D. F., Motzer, R. J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0813-8 · Cited by 259
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Boyer, M. J., Şendur, M. A. N., Rodríguez‐Abreu, D., Park, K., Lee, D. H., Çiçin, İ., Yumuk, P. F., Orlandi, F., Leal, T. A. B., Molinier, O., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03579 · Cited by 253
Progress and challenges of immunotherapy in triple-negative breast cancer
Zhu, Y., Zhu, X., Tang, C., Guan, X., & Zhang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188593 · Cited by 242
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 247
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
Chen, L.-T., Martinelli, E., Cheng, A., Pentheroudakis, G. E., Qin, S., Bhattacharyya, G. S., Ikeda, M., Lim, H. Y., Ho, G. F., Choo, S. P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.12.001 · Cited by 238
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Llovet, J. M., Montal, R., & Villanueva, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.028 · Cited by 234
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
(2019) · Korean Journal of Radiology · doi:10.3348/kjr.2019.0140 · Cited by 232
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy
Moik, F., Chan, W.-S. E., Wiedemann, S., Höeller, C., Tuchmann, F., Aretin, M., Fuereder, T., Zöchbauer‐Müller, S., Preusser, M., Pabinger, I., et al. (2020) · Blood · doi:10.1182/blood.2020007878 · Cited by 235
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
Reig, M., Sanduzzi‐Zamparelli, M., Forner, A., Rimola, J., Ferrer, J., Burrel, M., García‐Criado, Á., Díaz, A., Llarch, N., Iserte, G., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.10.020 · Cited by 253
Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer
Zhang, S., Mao, Y., Zhang, Z.-Y., Li, Z., Kong, C., Chen, H., Cai, P., Han, B., Ye, T., & Wang, L. (2021) · Theranostics · doi:10.7150/thno.54476 · Cited by 233
Overcoming Immune Evasion in Melanoma
Eddy, K., & Chen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238984 · Cited by 243
Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer
Elsholtz, F. H. J., Asbach, P., Haas, M., Becker, M., Beets‐Tan, R. G. H., Thoeny, H. C., Padhani, A. R., & Hamm, B. (2021) · European Radiology · doi:10.1007/s00330-020-07572-4 · Cited by 224
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
Amaria, R. N., Menzies, A. M., Burton, E. M., Scolyer, R. A., Tetzlaff, M. T., Antdbacka, R., Ariyan, C. E., Bassett, R. L., Carter, B., DAUD, A. I., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30332-8 · Cited by 221
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Marabelle, A., Andtbacka, R. H. I., Harrington, K. J., Melero, I., Leidner, R. S., de Baère, T., Robert, C., Ascierto, P. A., Baurain, J. F., Imperiale, M. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy423 · Cited by 216
IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer
Blomberg, O. S., Spagnuolo, L., Garner, H., Voorwerk, L., Isaeva, O. I., van Dyk, E., Bakker, N. A. M., Chalabi, M., Klaver, C., Duijst, M., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.014 · Cited by 225
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Mittendorf, E. A., Lu, B., Melisko, M., Hiller, J. A. P., Bondarenko, I., Brunt, A. M., Sergii, G., Petráková, K., & Peoples, G. E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2867 · Cited by 215
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Muir, C. A., Clifton-Bligh, R. J., Long, G. V., Scolyer, R. A., Lo, S., Carlino, M. S., Tsang, V., & Menzies, A. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab263 · Cited by 217
Imaging of Cancer Immunotherapy: Current Approaches and Future Directions
Nishino, M., Hatabu, H., & Hodi, F. S. (2018) · Radiology · doi:10.1148/radiol.2018181349 · Cited by 218
Self-citation
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer
Chen, Y., Wang, D., Li, Y., Lu, Q., Si, W., Bo, Y., Chen, X., Ye, Z., Fan, H., Liu, B., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.009 · Cited by 229
Future cancer research priorities in the USA: a Lancet Oncology Commission
Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S. N., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 212
Self-citation
Immune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 219
“Current guidelines recommend considering radiological assessment in context with clinical status (improvement in symptoms, weight), however evaluation of early tumor response can remain challenging.(23) OPTIMAL THERAPY DURATION.”
BackgroundMethod
Treatment after progression in the era of immunotherapy
Billan, S., Kaidar‐Person, O., & Gil, Z. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30328-4 · Cited by 205
Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma
Straathof, K. C. M., Flutter, B. R., Wallace, R., Jain, N., Loka, T., Depani, S., Wright, G., Thomas, S., Cheung, G. W.-K., Gileadi, T. E., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abd6169 · Cited by 203
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Abu‐Sbeih, H., Ali, F. S., Naqash, A. R., Owen, D. H., Patel, S. H., Otterson, G. A., Kendra, K. L., Ricciuti, B., Chiari, R., Giglio, A. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00320 · Cited by 201
Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
Anwar, H., Sachpekidis, C., Winkler, J. K., Kopp‐Schneider, A., Haberkorn, U., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3870-6 · Cited by 198
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
Jia, W., Gao, Q., Han, A., Zhu, H., & Yu, J. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0144 · Cited by 198
Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis
Abu-Sbeih, H., Ali, F. S., Wang, X., Mallepally, N., Chen, E., Altan, M., Bresalier, R. S., Charabaty, A., Dadu, R., Jazaeri, A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0577-1 · Cited by 191
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
Lee, C., Shah, A. Y., Rasco, D. W., Rao, A., Taylor, M. H., Simone, C. D., Hsieh, J. J.-D., Pinto, Á., Shaffer, D. R., Sarrió, R. G., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00241-2 · Cited by 195
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
Goldfarb, L., Duchemann, B., Chouahnia, K., Zelek, L. H., & Soussan, M. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0473-1 · Cited by 190
Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma
Cai, J., Song, L., Zhang, F., Wu, S., Zhu, G., Zhang, P., Chen, S., Du, J.-X., Wang, B., Cai, Y., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12607 · Cited by 206
“Patients underwent bimonthly magnetic resonance imaging (MRI) examinations to assess the therapeutic effects of anti-PD-1 treatment according to iRECIST guidelines [31].”
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27303-7 · Cited by 175
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
Song, Y., Zhang, B., Xin, D., Kou, X., Tan, Z., Zhang, S., Sun, M., Zhou, J., Fan, M., Zhang, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02179-2 · Cited by 178
Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis
Park, H. J., Kim, K. W., Pyo, J., Suh, C. H., Yoon, S., Hatabu, H., & Nishino, M. (2020) · Radiology · doi:10.1148/radiol.2020200443 · Cited by 162
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
Yamauchi, T., Hoki, T., Oba, T., Jain, V., Chen, H., Attwood, K. M., Battaglia, S., George, S., Chatta, G. S., Puzanov, I. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21619-0 · Cited by 174
18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma
Ito, K., Teng, R. S. Y., Schöder, H. M., Humm, J. L., Ni, A., Michaud, L., Nakajima, R., Yamashita, R., Wolchok, J. D., & Weber, W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.213652 · Cited by 174
Self-citation
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
Bröckelmann, P. J., Goergen, H., Keller, U. B., Meißner, J., Ordemann, R., Halbsguth, T. V., Sasse, S., Sökler, M., Kerkhoff, A., Mathas, S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0750 · Cited by 175
Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics
Dercle, L., Fronheiser, M., Lu, L., Du, S., Hayes, W., Leung, D. K., Roy, A., Wilkerson, J., Guo, P., Fojo, A. T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2942 · Cited by 177
Self-citation
Practical recommendations for using ctDNA in clinical decision making
Cohen, S. A., Liu, M. C., & Aleshin, A. A. (2023) · Nature · doi:10.1038/s41586-023-06225-y · Cited by 177
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Anagnostou, V., Ho, C., Nicholas, G. A., Juergens, R. A., Sacher, A. G., Fung, A. S., Wheatley‐Price, P., Laurie, S. A., Levy, B. P., Brahmer, J. R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02598-9 · Cited by 171
Self-citation
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
Beaver, J. A., Hazarika, M., Mulkey, F. A., Mushti, S. L., Chen, H., He, K., Sridhara, R., Goldberg, K. B., Chuk, M. K., Chi, D.-C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30846-x · Cited by 168
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
Chen, A. P., Sharon, E., Coyne, G. O., Moore, N., Foster, J. C., Hu, J. S., Tine, B. A. V., Conley, A. P., Read, W. L., Riedel, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303383 · Cited by 170
Self-citation
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
Nowak, A. K., Lesterhuis, W. J., Kok, P., Brown, C. S. B., Hughes, B. G. M., Karikios, D. J., John, T., Kao, S. C.-H., Leslie, C., Cook, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30462-9 · Cited by 167
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
Yang, J. C., Lee, D. H., Lee, J., Fan, Y., de Marinis, F., Iwama, E., Inoue, T., Rodríguez‐Cid, J. R., Zhang, L., Yang, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02747 · Cited by 165

Authors: Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., Hodi, F. S., Therasse, P., Hoekstra, O. S., Shankar, L. K., Wolchok, J. D., Ballinger, M., Caramella, C., & de Vries, E. G. E.
Affiliations: Queen's University (CA)
European Organisation for Research and Treatment of Cancer (BE)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
NewYork–Presbyterian Hospital (US)
Mayo Clinic (US)
National Institutes of Health (US)
Harvard University (US)
Institut de Recherches Internationales Servier (France) (FR)
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Memorial Sloan Kettering Cancer Center (US)
Genentech (US)
Institut Gustave Roussy (FR)
Corresponding author: Seymour, Lesley
ORCID: Seymour, Lesley
Bogaerts, Jan
Ford, Robert
Mandrekar, Sumithra
Litière, Saskia
Dancey, Janet
Chen, Alice
Hodi, F Stephen
Hoekstra, Otto S
Shankar, Lalitha K
Wolchok, Jedd D
Caramella, Caroline
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2017-03
Volume: 18
Issue: 3
Pages: e143-e152
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(17)30074-8
PMC: PMC5648544
OpenAlex: W2592144107
Cited by: 2,472
References: 37
Citations by year: 2026: 264 · 2025: 267 · 2024: 319 · 2023: 305 · 2022: 270 · 2021: 308 · 2020: 304 · 2019: 223 · 2018: 146 · 2017: 62
FWCI: 21.17
Type: journal article
Language: en
Update notices: erratum (2019-05-01)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Pure Amsterdam UMC (submittedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: National Cancer Institute (U10CA011488, P30CA008748)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords: iRECIST, cancer immunotherapy, response evaluation criteria, disease progression, immunomodulators, clinical trial data collection, data warehouse
MeSH terms: Humans, Immunotherapy, Neoplasms, Practice Guidelines as Topic, Disease Progression, Tumor Burden, Response Evaluation Criteria in Solid Tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks